Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 10872.145 | uM | inf | inf | 1.0423 | 1.0423 | 0.0000 | 0.0067 | 0.0000 | 1.6308 | |
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 12000.145 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0614 | 0.0000 | 0.6084 | |
| CAMA-1 | HR+ | Luminal | Sulindac sulfide | COX1/2 | COX | 10473.136 | uM | inf | inf | 0.9598 | 0.9598 | 0.0000 | 0.0241 | 0.0000 | 1.3186 | |
| HCC1395 | TNBC | Basal B | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 7436.095 | uM | inf | inf | 0.9643 | 0.9643 | 0.0000 | 0.0131 | 0.0000 | 1.3597 | |
| HCC1428 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 7443.098 | uM | inf | inf | 0.9399 | 0.9399 | 0.0000 | 0.0425 | 0.0000 | 0.9189 | |
| BT-483 | HR+ | Luminal | PD184352 | MEK | MAPK | 11855.155 | uM | inf | inf | 0.7132 | 0.7132 | 0.0000 | 0.3205 | 0.0000 | 0.7873 | |
| BT-483 | HR+ | Luminal | PD184352 | MEK | MAPK | 11855.155 | uM | inf | inf | 0.7132 | 0.7132 | 0.0000 | 0.3205 | 0.0000 | 0.7873 | |
| BT-483 | HR+ | Luminal | Pevonedistat | NAE1 | NAE1 | 11855.135 | uM | inf | inf | 0.7998 | 0.7998 | 0.0000 | 0.2110 | 0.0000 | 0.6394 | |
| CAMA-1 | HR+ | Luminal | Celecoxib | COX2 | COX | 10473.136 | uM | inf | inf | 0.9467 | 0.9467 | 0.0000 | 0.0581 | 0.0000 | 1.3186 | |
| BT-483 | HR+ | Luminal | PS-1145 | IKK | NFKB | 5908.065 | uM | inf | inf | 0.9395 | 0.9395 | 0.0000 | 0.1159 | 0.0000 | 0.5136 | |
| HCC1419 | HER2amp | Luminal | PS-1145 | IKK | NFKB | 7440.065 | uM | inf | inf | 0.9343 | 0.9343 | 0.0000 | 0.1126 | 0.0000 | 0.5818 | |
| 21NT | HER2amp | - | Ribavirin | 15383.211 | uM | inf | inf | 1.0074 | 1.0074 | 0.0000 | 0.0469 | 0.0000 | 1.0341 | |||
| BT-20 | TNBC | Basal A | FTase Inhibitor I | Ftase | MAPK | 11854.154 | uM | inf | inf | 0.8747 | 0.8747 | 0.0000 | 0.1104 | 0.0000 | 1.3146 | |
| 600MPE | HR+ | Luminal | JNK-IN-5A | JNK | JNK | 12224.144 | uM | inf | inf | 0.9302 | 0.9302 | 0.0000 | 0.0839 | 0.0000 | 1.0210 | |
| 600MPE | HR+ | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 5898.095 | uM | inf | inf | 0.3076 | 0.3076 | 0.0000 | 0.6877 | 0.0000 | 0.6975 | |
| 600MPE | HR+ | Luminal | PS-1145 | IKK | NFKB | 5898.065 | uM | inf | inf | 0.9898 | 0.9898 | 0.0000 | 0.1430 | 0.0000 | 0.6845 | |
| 600MPE | HR+ | Luminal | PS-1145 | IKK | NFKB | 5899.065 | uM | inf | inf | 0.8491 | 0.8491 | 0.0000 | 0.1182 | 0.0000 | 1.0946 | |
| BT-20 | TNBC | Basal A | Methotrexate | DHFR | Metabolism | 5903.084 | uM | inf | inf | 1.0102 | 1.0102 | 0.0000 | 0.0105 | 0.0000 | 1.2088 | |
| BT-474 | HER2amp | Luminal | Pemetrexed | TYMS/DHFR/GARFT | TYMS | 5906.095 | uM | inf | inf | 1.0129 | 1.0129 | 0.0000 | 0.0481 | 0.0000 | 0.6731 | |
| BT-483 | HR+ | Luminal | Selumetinib | MEK | MAPK | 11855.155 | uM | inf | inf | 0.7745 | 0.7745 | 0.0000 | 0.2804 | 0.0000 | 0.7873 | |
| BT-483 | HR+ | Luminal | ICRF-193 | TOP2 | TOP | 11855.157 | uM | inf | inf | 0.7596 | 0.7596 | 0.0000 | 0.2419 | 0.0000 | 0.7986 | |
| BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 10696.154 | uM | inf | inf | 0.9257 | 0.9257 | 0.0000 | 0.0501 | 0.0000 | 0.6070 | |
| 21MT-1 | HER2amp | - | Ribavirin | 15382.211 | uM | inf | inf | 0.9683 | 0.9683 | 0.0000 | 0.0416 | 0.0000 | 1.1714 | |||
| HCC1569 | HER2amp | Basal A | PD184352 | MEK | MAPK | 10872.155 | uM | inf | inf | 0.9297 | 0.9297 | 0.0000 | 0.0301 | 0.0000 | 1.5288 | |
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 12523.17 | uM | inf | inf | 0.8636 | 0.8636 | 0.0000 | 0.0444 | 0.0000 | 0.8990 |